Its been a good year for investors in OptiBiotix Health plc (LON:OPTI) with an increase in the share price from 17p to 80p over the last 12 months (370% increase), recognition and awards (see http://www.fool.co.uk/investing/2015/11/10/is-it-too-late-to-buy-2015-winners-fevertree-drinks-plc-205-afc-energy-plc-251-optibiotix-health-plc-280/ ) and a growing number of commercial deals. Not surprising when you consider the areas of healthcare that OptiBiotix is focused on in an era where chronic problems in societies are likely increase as consumption and demand grow.
OptiBiotix Health Plc recently announced it had filed two new patents covering its cholesterol-reducing product, which increases its total patents to 11, thus creating further valuable assets and opportunity on the route to commercialisation.
The question now is what’s to come in 2016?
A recent oversubscribed placing, consistent delivery by management who also took part in the placing to the tune of £110k, and a new target share price of 95.4p by its in house broker, Hybridan suggest there is a lot more to come ( http://www.shareprophets.com/views/17270/optibiotix-hybridan-ups-target-from-49p-to-954p-feel-free-to-ignore ). Recent interviews with the CEO seem to support this view (see http://dt.directorstalk.net/qa-with-stephen-ohara-chief-executive-officer-at-optibiotix-health-plc-lonopti/ & https://vimeo.com//148095557) with a focus on accelerating the commercialisation of existing products, extending technology platforms into new application areas, and building the product development pipeline. Many of the new developments represent high growth opportunities in large global markets which are equal to or greater than existing plans.
This is good news for shareholders in 2016 as the company now has a broad range of platforms with numerous product and numerous partnering opportunities. This builds company value and derisks the company as if one platform or product was unsuccessful the company would simply shift its focus to other platforms and products.
We asked the CEO at OptiBiotix Health plc his thoughts on this years progress.
Stephen OHara said ‘I am pleased with the progress of OptiBiotix Health plc in 2015 and feel we have the foundations and industry relationships in place to continue the rapid growth of the company in 2016 and beyond. We look forward to an exciting start to 2016 and continued strong progress on both commercial and scientific opportunities. On behalf of everyone at OptiBiotix Health plc I would like to thank investors for all their support throughout 2015 and look forward to an exciting future building a microbiome business with significant value for shareholders’.
